[Gastric inhibitory polypeptide (GIP) (author's transl]

Area of Science:

• Endocrinology
• Gastroenterology
• Metabolic Research

Background:

• Gastric inhibitory polypeptide (GIP) is secreted by the duodenum and jejunum in response to nutrient intake (glucose, fat, amino acids).
• GIP plays a crucial role as an incretin, augmenting glucose-stimulated insulin release from pancreatic beta-cells.
• Understanding GIP's physiological role is vital for metabolic and gastrointestinal research.

Purpose of the Study:

• To describe a sensitive radioimmunoassay method for quantifying GIP in serum samples.
• To establish the sensitivity and applicability of the GIP assay for determining fasting and postprandial levels.
• To explore the clinical and pathophysiological significance of GIP in various diseases.

Main Methods:

• Development and validation of a radioimmunoassay (RIA) for human serum GIP determination.
• Assessment of the RIA's lower limit of sensitivity.
• Measurement of fasting GIP levels in normal subjects using the developed RIA.

Main Results:

• The GIP radioimmunoassay demonstrated a sensitivity range of 30-50 pg/ml serum.
• The assay was sufficiently sensitive to measure fasting GIP levels in normal individuals (mean 287 +/- 59 pg/ml).
• The study discusses the implications of GIP levels in conditions such as obesity, diabetes mellitus, and duodenal ulcer disease.

Conclusions:

• A sensitive and reliable radioimmunoassay for GIP has been established.
• This assay enables the accurate measurement of GIP, crucial for understanding its incretin function.
• Altered GIP levels may be implicated in the pathophysiology of metabolic and gastrointestinal disorders, warranting further investigation.